Introduction
Anagrelide is a platelet lowering agent used in the clinic as part of the armamentarium to treat essential thrombocythemia (ET) [1;2] . Although originally developed as an inhibitor of platelet aggregation [3] initial studies in humans demonstrated that the drug had profound thrombocytopenic effects which had not been manifested during preclinical studies in animal models [4] . Further studies demonstrated that the platelet lowering effects were due to a potent inhibition of megakaryopoiesis [5;6] . Subsequent efforts to explain the differential responses in rodents and humans attributed the anti-megakaryopoietic activity to a metabolite of the drug [7] or to species-specific inhibition of thrombopoietin (TPO) receptorstimulated tyrosine phosphorylation [8] . However these claims could not be reconciled with results from our own laboratory comparing between the biological activities of anagrelide and its human metabolites [9] or analysing the effects of the parental drug on TPO receptorstimulated early signal transduction events [10] . On the other hand, further work showed that anagrelide inhibits the expression of various key transcription factors involved in megakaryocyte (MK) development and platelet production, namely GATA-1, FOG-1, FLI-1 and NF-E2 [10] . Anagrelide also inhibits a Type III phosphodiesterase (PDE III) found in platelets and the myocardium [11] . This activity underlies the anti-platelet aggregation effect of the drug but does not appear to be related to its anti-megakaryopoietic properties [9;10] .
Thus, despite these advances in the understanding of the mode of action of the drug, to date the primary target accounting for the platelet-lowering effect has remained elusive.
Gene expression profiling using DNA microarrays has been successfully used for over a decade to elucidate mechanisms underlying biological pathways and to generate testable hypothesis on the mode of action of poorly characterised pharmacological agents [12;13] .
Therefore, in an attempt to gain further insights into the mechanism of action of anagrelide we have compared the transcriptional profiles of primary cultures of developing human MKs growing in the absence or presence of the drug. Here we report the outcome of this approach and the results of ensuing biochemical studies which indicate that anagrelide In addition, this study uncovers new potential regulators of MK development.
Methods

Drugs
Anagrelide hydrochloride was purchased from Tocris Bioscience (Bristol, UK). Salubrinal, cilostamide and MG-132 were from Calbiochem (Nottingham, UK). Stock solutions were made in DMSO, stored in aliquots at -20 o C and when required diluted in culture medium immediately before experiments.
Cell culture and drug treatments
MKs were generated ex-vivo from human neonate hematopoietic cells using a two-step liquid culture system as previously described [10] . In brief, umbilical cord blood-derived Biosystems, Warrington, UK) as previously described [10] . Probes are listed in Table S1 . β-glucuronidase (GUSB) and TATA-box binding protein (TBP) were used as internal controls.
Flow cytometry
MK-specific antigen expression was monitored by flow cytometry using fluorescein isothiocyanate-conjugated anti-CD61 (clone Y2/51, Dako, Ely, UK) and allophycocyaninconjugated anti-CD42b (clone HIP1, BD Biosciences, Oxford, UK) antibodies as previously described [9] .
Western blotting
Aliquots of ~2 x 10 6 cells were washed with ice-cold phosphate buffered saline and resuspended by adding 70 µL ice-cold lysis buffer (10 mM Tris HCl, pH 7.4, 100 mM NaCl, 10% glycerol, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulphate, 
Results
The global gene expression signature of anagrelide
To distinguish transcriptional changes related to the anti-megakaryocytic activity of anagrelide we compared the genome-wide expression profiles of cells treated with TPO for 4 days in the presence of the drug or an equivalent amount of vehicle. Q-PCR analysis confirmed that under these conditions anagrelide reduced markedly the rise in the expression of a subset of representative genes associated with MK development (Fig. S1 ), as previously reported [10] .
Pairwise comparisons between the microarray signals from control and anagrelide-treated samples using a 2 fold-change cut-off and a statistical threshold set at p<0.05, identified 412 gene tags fitting these criteria. These represented 328 annotated genes, 214 of which were down-regulated and the rest were up-regulated (Table S2 ). Functional enrichment analysis of Gene Ontology (GO) terms revealed that among the down regulated genes there was a statistically significant overrepresentation of categories related to the components and function of platelets, such as integrin binding, cell adhesion, coagulation, response to wounding and secretory granules (Fig. 1) . In contrast, for the up-regulated genes there was a significant enrichment in terms associated with immune and inflammatory responses, and cytokine/chemokine activity (Fig. 1 ). Genes present in the different overrepresented functional categories are listed in Tables S3 and S4. Transcriptional control is fundamental to the orchestration of the MK differentiation process.
Hence, the list of 412 gene tags was also inspected to identify functional subsets of genes that might potentially affect transcriptional responses. This inspection revealed that anagrelide affected the expression of 23 genes corresponding to proteins which could be directly involved in the regulation of gene transcription ( Table 1) . Twelve of these transcripts were up-regulated and the rest were down-regulated. Eleven genes in this category and the cytokine IL8 were selected for further verification by Q-PCR. In addition, the effect of the 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Anagrelide increases the expression of genes activated by ATF4
Among the genes listed in Table 1 , the human homolog of Drosophila tribbles 3 (TRIB3) stood out as being strongly up-regulated by anagrelide. TRIB3 expression is known to be regulated by the transcription factor ATF4 [17;18] . In line with this notion, pathway enrichment analysis of the microarray data set against the curated database of biological pathways Reactome ranked the activation of ATF4 as one of the top three statistically significant over-represented events (p<0.01). Indeed, this analysis uncovered five additional genes under the transcriptional control of ATF4 which were up-regulated by anagrelide (Table 2 ).
To assess in more depth the role of ATF4 in the response to anagrelide, we examined the effect of a short window of exposure to the drug on the expression of ATF4 mRNA and three of its target genes (ATF3, DDIT3 and TRIB3). To this end cells were treated with anagrelide for a 24 hour interval, starting at different time points after the initiation of the differentiation process. As shown in Fig. 3 , this treatment schedule revealed that during the first 2 days of differentiation there was little or no response to the drug. However, following this refractory phase TRIB3, DDIT3 and ATF3 expression was seen to increase sharply, the response becoming stronger the longer the pre-incubation time, even though the period of exposure to the drug remained the same. In contrast, ATF4 expression only increased at a much later stage and to a lesser degree. Thus, these results suggest that anagrelide stimulates ATF4- 
The transcriptional response to anagrelide may depend on the megakaryocyte differentiation state
To ascertain whether the timing of exposure to anagrelide also influenced the degree of change in the expression of genes other than those directly controlled by ATF4, we examined the levels of the transcriptional regulators JUN, MAX, TAL1 and NFIB in the above experimental setting. As shown in Fig. S3 , in the case of JUN and MAX, the effect of anagrelide was clearly larger if the drug was added at later time points. In the case of TAL1 and NFIB, the response to the 24h treatment with the drug was quite small, but nevertheless a similar trend was observed. Taken together, these findings suggest that the transcriptional response to anagrelide is orchestrated via a mechanism which may be dependent on the differentiation state of the cell.
Anagrelide stimulates signalling through eIF2α/ATF4
In other systems activation of ATF4-mediated transcription is triggered by the upstream phosphorylation of the α-subunit of the eukaryotic translation initiation factor-2 (eIF2α) which in turn promotes an increase in ATF4 translation [19] . Consistent with this notion, anagrelide stimulated a rapid phosphorylation of eIF2α (Fig. 4A ) and an increase in ATF4 protein levels; the latter however, could only be unravelled in the presence of the proteasomal inhibitor MG132 (Fig. 4B) .
The phosphorylation of eIF2α is connected to the inhibition of megakaryocyte growth
To obtain evidence that the phosphorylation state of eIF2α was related to the anti-MK activity of anagrelide, we studied the response to salubrinal, a known inhibitor of eIF2α dephosphorylation. Salubrinal was tested in MK cultures at 75 µM as this is the 
Discussion
In the present study we have identified the global gene expression signature of anagrelide in a further attempt to advance our understanding on its mode of action. To this end we have used a well-established ex-vivo model system of megakaryopoiesis in which human CD34 + -derived hematopoietic progenitor cells were treated with the drug at a concentration of 0.3
µM for a period of four days under conditions which would otherwise promote terminal MK differentiation. These treatment conditions were selected on two accounts: 1) the chosen dose of anagrelide does not affect the proliferation of hematopoietic progenitors or their differentiation into other lineages [21] ; 2) at this dose, a four days exposure constitutes the earliest time point at which a consistent transcriptional response to the drug is observed when examining the changes in expression of a selected group of genes [10] . Using this approach we found 328 genes that were differentially expressed as a result of anagrelide treatment. Close to two thirds of the genes in this data set were down-regulated. Among these we detected a significant over-representation of functional categories associated with the contents of platelets and their functions, altogether encompassing forty four genes.
These included genes encoding for proteins involved in platelet activation, secretion, adhesion, aggregation, clot formation and wound healing. These results are consistent with the overall action of anagrelide as an inhibitor of thrombopoiesis, therefore endorsing the validity of the transcriptome analysis. In addition, we also identified 114 genes in our data set that were up-regulated. The latter included a significantly high proportion of genes associated with immune and inflammatory responses and with cytokine/chemokine activity.
This might suggest that by stalling the MK differentiation programme, the cell acquires phenotypic characteristics of other myeloid lineages. Alternatively, the possibility that in-vivo, the residual thrombopoietic activity that takes place in the presence of anagrelide could produce MKs and platelets with altered functional properties cannot be discounted. One gene present in this group was IL8, a pro-inflammatory cytokine also found to be elevated in primary myelofibrosis [22] . In this respect, our findings could be relevant to concerns raised by the PT-1 trial where an increased frequency of myelofibrotic transformation [23] and a greater increase in reticulin fibrosis over time [24] were seen in ET patients treated with anagrelide when compared to those treated with hydroxyurea. However, whether anagrelide actually promotes fibrosis is currently unknown; this question could only be addressed by comparing its effect against an untreated cohort.
In accordance with previous work suggesting that anagrelide affects the transcriptional control of MK differentiation [10] , we also found significant changes in the expression of 23 genes that encode putative transcriptional regulators. However, unlike in our previous Q-PCR-based expression study where we found that the drug treatment led to a decrease in the mRNA levels for the transcription factors GATA1, FOG1, FL1 and NFE2 [10] , we did not find these genes listed in our microarray data set. Nevertheless, we could confirm by Q-PCR that their expression was also reduced by anagrelide in the current samples, although by less than 2-fold, which was the cut-off of the microarray analysis.
It has been recently reported that anagrelide inhibits megakaryopoiesis owing to its PDEIII inhibitory activity by stimulating cAMP/PKA signalling and subsequently targeting the transcription factor E2A (TCF3), down-regulating its mRNA levels [25] . Nevertheless, both our microarray data set and our Q-PCR analysis showed no evidence that anagrelide reduced TCF3 mRNA levels at the concentration tested. Furthermore, of all the genes that we subsequently verified by PCR, none was found to respond to the PDEIII inhibitor cilostamide, suggesting that the majority of the gene expression changes induced by anagrelide were not due its PDEIII inhibitory activity. Indeed, this interpretation is consistent with previous findings showing that pure PDEIII inhibitors have negligible effects on [30] , or signal transduction [31] in the MK lineage.
However, with the exception of JUN [32] , TAL1 (reviewed in [33;34] ), and more recently NFIB [35] , the expression or role of these genes in megakaryopoiesis has not been studied further. In our study, the gene most strongly down-regulated by anagrelide in this category was IRX3. This gene encodes a homeobox transcription factor previously implicated in the development of the nervous system [36] . Future work will determine whether this gene is also a major player in MK development.
Prominent among the genes up-regulated by anagrelide was TRIB3, a member of an emerging group of pseudo-kinases, increasingly implicated in the regulation of cellular metabolism, stress responses, cell proliferation and differentiation (reviewed in [37;38] ). In the context of haematopoiesis TRIB3 has been reported to undergo up-regulation by erythropoietin and has been associated with erythroid progenitor cell survival [39] and differentiation [40] . In contrast, in line with our findings, TRIB3 has been previously cited in a microarray data set among the down regulated genes of a TPO-response signature [41] .
However, its role in megakaryopoiesis is yet to be established. The finding in the present study that it was up-regulated by anagrelide raises the possibility that it may act as a repressor of this process. In this respect it is noteworthy that in other systems TRIB3 has been shown to act as a transcriptional repressor by interacting with a number of transcription factors, including ATF4 [42] , DDIT3 [18] , C/EBPβ [43] and PPARγ [44] . In addition, it has [45] and MEK1 [46] as well as the E3 ubiquitin-protein ligase SMURF1 [47] . Whether any of these interactions might play a role in the inhibition of megakaryopoiesis remains to be determined.
A major finding of the present study was that anagrelide up-regulated the expression of genes that are under the transcriptional control of ATF4, TRIB3 being one of them. In other systems the gene expression changes orchestrated by ATF4 occur as a result of a selective increase of its translation [48] . The increase in ATF4 translation occurs as a consequence of the phosphorylation of eIF2α, an event which allows the scanning ribosomes to bypass an inhibitory upstream open reading frame (ORF) of the mRNA, and re-initiate translation from the downstream coding ORF [19] . In the present study initial experiments to detect ATF4 in immunoblots obtained from MK cultures treated with anagrelide were unsuccessful. ATF4 is an unstable protein readily degraded by the proteasome [49] , raising the possibility that the failure to detect this protein was due to its rapid degradation. To test for this possibility, cultures were pre-treated with the proteasomal inhibitor MG132, and in this case a clear increase in ATF4 protein levels was detected after treatment with anagrelide. These results suggest that the drug causes a transient increase in ATF4 that is readily detected only when the proteasome is inhibited. Importantly, in our study anagrelide also caused a rapid increase in the phosphorylation of eI2Fα. The phosphorylation state and activity of this protein are known to be negatively regulated by the phosphoprotein phosphatase PP1 [50] .
A compound called salubrinal has been shown to inhibit the ability of PP1 to dephosphorylate eIF2α, thus diminishing the negative effect exerted by this mechanism [20] . Accordingly, we found that salubrinal increased eIF2α phosphorylation and mimicked the anti-MK activity of anagrelide. Taken together our findings indicate that anagrelide acts upstream of eIF2α on a pathway that leads to its activation.
The phosphorylation of eIF2α constitutes the point of convergence of a number of upstream stress signalling protein kinases. Concomitantly with the increase in ATF4 protein levels this to restore cellular homeostasis [48] . Because of the integrative nature of this pathway, its downstream consequences were termed the "integrated stress response" (ISR) [51] . The ISR is also activated by diverse chemical entities, including cannabinoids [52] , certain phenylamaleimides [53] and the plant alkaloid derivative halofuginone [54] . Interestingly, the latter is known for its selective inhibition of helper T cell differentiation [54] . Thus, like the effects of these substances, our findings raise the possibility that anagrelide inhibits MK Our previous studies have underscored the selectivity of anagrelide for the MK lineage [9;10;21] . A possibility to explain this behaviour of the drug is that its primary target is a MKspecific factor which is induced exclusively as part of this lineage differentiation programme.
The finding that upon a short exposure to anagrelide the magnitude of the increase in the expression of ATF4-regulated genes as well as the changes in the expression of other key transcription factors, escalate when the drug is added after the process of differentiation has already started, is entirely consistent with this possibility. These findings are also in keeping with our previous report showing that virtually no transcriptional response to anagrelide is observed within the first two days of continuous exposure to the drug [10] .
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